Monthly Archives: February 2022

Bristol-Myers Squibb Update

Posted on February 27, 2022 by Stephen Percoco

Raising 2022 Estimate and Adding 2023, Maintaining Outperform Rating and Price Target of $73 Bristol-Myers Squibb Company (BMS) achieved many operational milestones in 2021, advancing its development pipeline through clinical trials, new drug applications and regulatory approvals.  At its November … Continue reading →

Posted in BMY, Health Care | Tagged | Comments Off on Bristol-Myers Squibb Update

The Drivers of Large Cap Stock Performance in 2021

Posted on February 2, 2022 by Stephen Percoco

Estimated Returns by Sectors, Industry Groups and Industries Large cap stocks, as measured by the Lark Research Large Cap index (the “Index”) which currently mirrors the S&P 500, turned in another impressive performance in 2021.  The Index posted a price … Continue reading →

Posted in Energy, Financials, Market Commentary, Real Estate, Sectors, Technology, Utilities | Tagged , , , | Comments Off on The Drivers of Large Cap Stock Performance in 2021

DHC Announces Sales of Joint Venture Interests in Certain Office Properties

Posted on February 2, 2022 by Stephen Percoco

Sales Raise Over $1 Billion, Giving the Trust the Means to Retire the 9.75% Senior Notes due 2025 When They Become Callable in June 2022. DHC announced on January 31 that it has entered into a joint venture with two … Continue reading →

Posted in DHC, Real Estate | Tagged | Comments Off on DHC Announces Sales of Joint Venture Interests in Certain Office Properties